CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Acacia Pharma Group PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Acacia Pharma Group PLC
The Officers Mess Business Centre
Royston Road
Phone: +44 1223919760p:+44 1223919760 CAMBRIDGE, CB22 4QH  United Kingdom Fax: +44 1223919769f:+44 1223919769

This company was Merged or Acquired on 6/9/2022.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Acacia Pharma Group plc is a United Kingdom-based commercial stage biopharmaceutical company. The Company is focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy. It operates through one reportable segment, being the development and commercialization of intellectual property through direct sale of the protected products in the United States. The Company has a portfolio of differentiated hospital products primarily for use by anesthesia and surgical teams and a late-stage development candidate targeting oncologists. The Company’s pipeline product, APD403 is a selective dopamine antagonist for chemotherapy induced nausea and vomiting (CINV).

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202112/31/2021Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board ScottByrd 4/7/2020 3/6/2018
Chief Executive Officer, Executive Director MichaelBolinder 1/1/2022 11/1/2017
Chief Financial Officer GaryGemignani 56 1/1/2022 2/29/2020
6 additional Officers and Directors records available in full report.

Business Names
Business Name
0PNT
Acacia Pharma Ltd
ACPH

General Information
Outstanding Shares: 100,923,133 (As of 3/15/2022)
Stock Exchange: EBR
Fax Number: +44 1223919769


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, December 6, 2024